Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eftansomatropin - Genexine/Handok

Next Previous
Search
Drug Profile

Eftansomatropin - Genexine/Handok

Alternative Names: Eftansomatropin alfa; GX-H9; hGH-hyFc; HL 2356; HyTropin; Recombinant somatropin fusion protein; TJ 101

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genexine
  • Developer Genexine; Handok Inc
  • Class Growth hormones; Hormonal replacements; Recombinant fusion proteins
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 09 Jan 2025 No development reported - Phase-III for Somatotropin deficiency (In adults) in South Korea (SC) (Handok pipeline; January 2025)
  • 31 Aug 2023 I-Mab Biopharma announces intention to file BLA for Somatotropin deficiency (In children) in China in 2024
  • 17 Aug 2023 Efficacy and adverse events data from a phase III trial in Somatotropin deficiency released by I-Mab Biopharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top